Peptide receptor radionuclide therapy in non-neuroendocrine tumours - a field report

被引：0
|
作者：
Nilica, B. [1 ]
机构：
[1] Univ Klin Nukl Med Innsbruck, Innsbruck, Austria
来源：
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING | 2016年 / 43卷
关键词：
D O I：
暂无
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
EPW43
引用
收藏
页码：S223 / S223
页数：1
相关论文
共 50 条
  • [41] Peptide Receptor Radionuclide Therapy as First Line Systemic Treatment in Advanced Inoperable/Metastatic Neuroendocrine Tumours
    Satapathy, Swayamjeet
    Sood, Ashwani
    Sood, Apurva
    Mittal, Bhagwant
    JOURNAL OF NUCLEAR MEDICINE, 2020, 61
  • [42] Peptide receptor radionuclide therapy proves to be safe and immediately efficient in elderly patients with symptomatic neuroendocrine tumours
    Duan, H.
    Dolliner, P.
    Dobrozemsky, G.
    Raderer, M.
    Hoffmann, M.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2013, 40 : S199 - S200
  • [43] The College of Nuclear Physicians of South Africa Practice Guidelines on Peptide Receptor Radionuclide Therapy in Neuroendocrine Tumours
    Lawal, I
    Louw, L.
    Warwick, J.
    Nyakale, N.
    Steyn, R.
    Lengana, T.
    Ellmann, A.
    Kotze, T.
    Vangu, M.
    Vorster, M.
    Sathekge, M.
    SOUTH AFRICAN JOURNAL OF SURGERY, 2018, 56 (03) : 55 - 64
  • [44] Efficacy and tolerability of peptide receptor radionuclide therapy (PRRT) in advanced metastatic bronchial neuroendocrine tumours (NETs)
    Mirvis, Eitan
    Toumpanakis, Christos
    Mandair, Dalvinder
    Gnanasegaran, Gopinath
    Caplin, Martyn
    Navalkissoor, Shaunak
    LUNG CANCER, 2020, 150 : 70 - 75
  • [45] Personalized 177Lu-octreotate peptide receptor radionuclide therapy of neuroendocrine tumours: a simulation study
    Michela Del Prete
    François-Alexandre Buteau
    Jean-Mathieu Beauregard
    European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44 : 1490 - 1500
  • [46] The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours
    Zaknun, John J.
    Bodei, L.
    Mueller-Brand, J.
    Pavel, M. E.
    Baum, R. P.
    Hoersch, D.
    O'Dorisio, M. S.
    O'Dorisiol, T. M.
    Howe, J. R.
    Cremonesi, M.
    Kwekkeboom, D. J.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2013, 40 (05) : 800 - 816
  • [47] The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours
    John J. Zaknun
    L. Bodei
    J. Mueller-Brand
    M. E. Pavel
    R. P. Baum
    D. Hörsch
    M. S. O’Dorisio
    T. M. O’Dorisiol
    J. R. Howe
    M. Cremonesi
    D. J. Kwekkeboom
    European Journal of Nuclear Medicine and Molecular Imaging, 2013, 40 : 800 - 816
  • [48] Personalized 177Lu-octreotate peptide receptor radionuclide therapy of neuroendocrine tumours: a simulation study
    Del Prete, Michela
    Buteau, Francois-Alexandre
    Beauregard, Jean-Mathieu
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2017, 44 (09) : 1490 - 1500
  • [49] Can peptide receptor radionuclide therapy be safely applied in florid bone metastases of gastroenteropancreatic neuroendocrine tumours?
    Sabet, Amir
    Yong-Hing, Charlotte
    Ezziddin, Khaled
    Ahmadzadehfar, Hojjat
    Guhlke, Stefan
    Gruenwald, Frank
    Biersack, Hans Juergen
    Ezziddin, Samer
    JOURNAL OF NUCLEAR MEDICINE, 2012, 53
  • [50] Assessment of somatostatin receptor expression in predicting results of PRRT (peptide receptor radionuclide therapy) in disseminated neuroendocrine tumours (NET)
    Hubalewska-Dydejayk, Alicja B.
    Sowa-Staszczak, Anna
    Trofimiuk, Malgorzata
    Stefanska, Agnieszka
    Wierzchowski, Wojciech
    Kunikowska, Jolanta
    Pach, Dorota
    Tomaszewska, Romana
    ENDOCRINE JOURNAL, 2010, 57 : S443 - S443
12345